Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rafabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 20/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 12/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 9/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rafabegron SCHEMBL7606623 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Rafabegron SCHEMBL3694097 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Rafabegron SCHEMBL29361441 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Rafabegron SCHEMBL7865766 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Rafabegron SCHEMBL678589 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL7865755 | 0.92 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6906032 | 0.92 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7593273 | 0.89 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6911229 | 0.89 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7870408 | 0.89 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230210-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | claimed |
| EP-0801059-B1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-06-27 | — | — | EP | claimed |
| WO-2001036375-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-25 | — | — | WO | claimed |
| EP-0801059-A1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-10-15 | — | — | EP | claimed |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | SMITHKLINE BEECHAM P.L.C. | 2003-04-17 | — | — | US | disclosed |
| EP-1230210-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-1128845-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTDIABETIC AGENT | SMITHKLINE BEECHAM PLC (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-0801059-B1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001036375-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000027434-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
| EP-0801059-A1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | ADRB1, ADRB2, ADRB3 | ADRB3 3/4885ADRB1 1/4885ADRB2 2/4885 |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | ADRB3 6/4885ADRB1 11/4885ADRB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.